Protein Kinase Inhibitors: Insights into Drug Design from Structure
By M. Noble, J. Endicott, L. Johnson. Science, 2004
1,202 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/94a06b90af977bb9a1ab56bd62b61ec6af86706b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Andriy Kryshtafovych
- Andrej Sali
- Krzysztof Fidelis
- David T. Jones
- Torsten Schwede
- Ian A. Wilson
- L. Meijer
- Rhiju Das
In Hematology
In Molecular Biology
- Torsten Schwede
- Andrej Sali
- Yang Zhang
- Ben M. Webb
- Andriy Kryshtafovych
- Jinbo Xu
- Krzysztof Fidelis
- David Baker
Citations in the corpus
- Protein Secondary Structure Prediction Using Cascaded Convolutional and Recurrent Neural Networks (2016, methodology): “Structural understanding is not only critical for protein analysis, but also meaningful for practical applications including drug design [Noble et al., 2004].”
- Outcome of a Workshop on Applications of Protein Models in Biomedical Research (2009, background): “Other applications of structural models involve the ‘‘optimiza-tion’’ of hits from virtual screening or high-throughput screening by detailed examination of the ligand-protein interactions and the exploitation of new contacts with the protein via ligand modi-fication (Noble et al., 2004).”
- Recent applications of protein crystallography and structure-guided drug design. (2005, background): “Kinases and phosphatases Reversible protein phosphorylation is a major control mechanism in eukaryotic cells and identification of selective kinase and phosphatase inhibitors is an area of intense current interest [23,24 ,25].”
- Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. (2005, background): “Activating mutations of protein kinases contribute to the development of human cancers (1) and have led to the development of kinase inhibitors that target these oncogenic forms (2).”
- Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “The active or inactive state of the protein kinase is determined by the position of the A-loop, including the DFG motif at its N-terminal, which has various conformations [28, 98, 134, 135].”
- Features of selective kinase inhibitors. (2005, background): “For example, almost all ATP-competitive kinase inhibitors satisfy at least one of the hydrogen bonds that is made between the adenine ring of ATP and the kinase [50].”
- Binding of Small-Molecule Ligands to Proteins: “What You See” Is Not Always “What You Get” (2009, neutral): “…have been used to study the role of crystallographic waters in binding thermodynamics (Barillari et al., 2007; Hamelberg and McCammon, 2004; Lu et al., 2006; Olano and Rick, 2004; Zhang and Hermans, 1996; see also Helms and Wade [1995, 1998a, 1998b] for desolvation of a buried binding cavity).”
- Rational Approaches to Improving Selectivity in Drug Design (2012, background): “9 From a drug discovery perspective, the aim is to hit only one or a subset of kinases along the biochemical pathway of interest while avoiding other kinases for which inhibition may result in adverse effects.”
- Pharmacological inhibitors of glycogen synthase kinase 3. (2004, background): “The overall shapeissharedbyallkinases,withasmallN-terminallobe, which consists mostly of b-sheets and a large C-terminal lobe, which is formed essentially of a-helices [ 2 ] .T he ATP-binding pocket is located between the two lobes.”